Riskpilot← Back to searchSign inGet full accessRinaPharm AB
ABActiveOrg 5591526693Smala Gränd 3Other non-specialised retail sale · NACE 4712Est. 20180 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
SEK -15K
-105% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK -15K | -105% |
| Total assets | SEK 17,9M | +4% |
| Equity | SEK 17,9M | +4% |
| Employees | 0 | — |
Legal name
RinaPharm AB
Org number
5591526693
Legal form
Aktiebolag
NACE code
4712 · Other non-specialised retail sale
Founded
15 mars 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Import och export av medicinsk utrustning, läkemedel, hälsokostprodukter samt konsultverksamhet inom hälsa.
Address
Smala Gränd 3
Email
frealbse@yahoo.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −1 | −14 | −15 | −24 | −16 | −39 | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — | — | — |
| EBIT | −1 | −14 | −15 | −24 | −16 | −39 | 0 |
| Net financials | 8 701 | 7 067 | 4 415 | — | −357 | 359 | −15 |
| Profit before tax | 6 871 | 6 919 | 4 399 | −24 | −373 | 320 | −15 |
| Tax | −0 | −0 | −0 | −0 | — | — | — |
| Net profit | 6 871 | 6 919 | 4 399 | −24 | −373 | 320 | −15 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 8 136 | 13 717 | 17 888 | 17 680 | 17 119 | 17 244 | 17 923 |
| Equity | 6 921 | 13 666 | 17 888 | 17 680 | 17 119 | 17 244 | 17 923 |
| Long-term debt | 0 | 0 | 0 | 0 | — | — | — |
| Short-term debt | 1 215 | 51 | 0 | 0 | — | — | — |
| Total debt | 1 215 | 51 | — | — | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20182024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182024
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20182024
Net profit margin
-1536400.0%
This company
8.1%
Market median
-18968001% vs market
20182024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-03-01 – 2018-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RinaPharm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Behrouz Rezakhani | Deputy Board Member | 0 companies |
| Freidoun André Albertioni | Board of Directors | 0 companies |